Table 3.
Association of baseline clinicopathologic characteristics and number of cumulative marker score in the total cohort.
| Systemic Inflammatory Markers | |||||
|---|---|---|---|---|---|
| Variables | 0 (N = 54) | 1 (N = 110) | 2 (N = 91) | 3 (N = 5) | p-Value |
| Age (years), 95%CI | 61.0 (59.0–63.5) | 63.0 (61.0–64.0) | 63.0 (60.0–65.0) | 56.0 (46.0–66.0) | 0.21 |
| PSA (ng/ml), 95%CI | 5.65 (4.97–6.62) | 5.68 (5.39–6.08) | 5.30 (4.92–5.92) | 9.02 (6.09–9.40) | 0.04 |
| PSA density (ng/ml/cc), median (95%CI) | 0.11 (0.10–0.13) | 0.12 (0.10–0.14) | 0.12 (0.10–0.13) | 0.18 (0.11–0.19) | 0.06 |
| Prostate volume (ml), median (95%CI) | 50.0 (43.4–52.5) | 49.0 (45.0–52.0) | 50.0 (45.0–56.0) | 52.0 (32.0–60.0) | 0.86 |
| ECE, n (%) | 11 (20.4) | 30 (27.3) | 26 (28.6) | 4 (80.0) | 0.03 |
| Pathological ISUP ≥2, n (%) | 8 (14.8) | 37 (33.6) | 44 (48.3) | 5 (100.0) | 0.001 |
95%CI = 95% confidence interval for median; ECE = extracapsular extension; ISUP = International Society of Urological Pathology.